About Vivimed Labs Limited
Data last updated:
Vivimed Labs Limited is a public limited company based in Bidar, Karnataka, India. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional. It operates in the personal care and skincare products segment of the FMCG sector. It was incorporated on 22 September 1988.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN L02411KA1988PLC009465. Its GSTIN is 29AAACV6060A1ZL (Karnataka). The company holds 10 GST registrations, of which 7 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 532660 and NSE: VIVIMEDLAB.
The company has an authorised share capital of ₹111 Cr and a paid-up capital of ₹16.58 Cr. It was formerly known as Emgi Pharmaceuticals & Chemicals Limited and Emgi Pharmaceuticals & Chemicals Private Limited. It is led by directors including Santosh Varalwar (Managing Director) and Manohar Rao Varalwar (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Plot No. 78 – A Kolhar Industrial Area Bidar, Karnataka, India – 585403.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹69.99 Cr, a decline of 39.8% compared to the previous year. For the same year it recorded a net loss of ₹176.47 Cr (net margin -252.1%) and EBITDA of -₹152.43 Cr (EBITDA margin -217.8%).
The company has about 59 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Vivimed Labs. As per MCA filings, the company has open charges of ₹932.51 Cr and satisfied charges of ₹791.99 Cr on record. Court records list 131 cases involving the company, including 20 filed by the company and 111 filed against it; 35 cases are pending. The company has 159 deals on record (151 market trades, 7 funding rounds, 1 secondary share transfer), with disclosed funding of ₹181.1 Cr; the latest was in February 2026. Its 8 peer companies in the FMCG industry (API Manufacturers, Personal Care and Skin Care), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 5 smaller; the largest is Richter Themis Medicare (India) Private Limited with revenue of ₹122.69 Cr.
The last known website on record is vivimedlabs.com.
Company details
Name history
Vivimed Labs has undergone 2 name changes throughout its history. The company was previously known as Emgi Pharmaceuticals & Chemicals Limited, and Emgi Pharmaceuticals & Chemicals Private Limited. The current legal name is Vivimed Labs Limited.
| Company Name | Status |
|---|---|
| Vivimed Labs Limited | Current |
| Emgi Pharmaceuticals & Chemicals Limited | Previous |
| Emgi Pharmaceuticals & Chemicals Private Limited | Previous |
Contact details
Vivimed Labs Limited's registered office is in Bidar, Karnataka. Its website is vivimedlabs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No. 78 – A Kolhar Industrial Area Bidar, Karnataka, India – 585403
- IndustryFMCG, Personal Care & Skincare Products
To see the full contact details of Vivimed Labs Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Vivimed Labs operates one associated brand: Vivimed Labs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Active pharmaceutical ingredients, formulations, and specialty chemicals are manufactured. | vivimedlabs.com |
Business activity
The main business activity of Vivimed Labs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Vivimed Labs Limited, buy the company report.
Financials of Vivimed Labs Limited
FY 2025-26 filings availableVivimed Labs Limited reported revenue of ₹69.99 Cr (down 39.8% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 69.99 | 116 | 149 | 187 | 237 | 861 | 1,059 |
| Revenue growth | -39.8% | -22.0% | -20.3% | -21.2% | -72.5% | -18.6% | - |
| EBITDA | (152) | (13.01) | (32.88) | (187) | (7.85) | 31.51 | 10.24 |
| EBITDA margin | -217.8% | -11.2% | -22.1% | -99.9% | -3.3% | +3.7% | +1.0% |
| Profit before tax | (176) | (31.84) | (45.82) | (331) | (64.85) | (69.87) | (109) |
| Net profit | (176) | (31.96) | (45.44) | (329) | (67.67) | (71.90) | (109) |
| Net profit margin | -252.1% | -27.5% | -30.5% | -175.6% | -28.5% | -8.4% | -10.3% |
| EPS (₹) | (20.53) | (3.85) | (5.48) | (39.62) | (8.16) | (8.67) | (13.16) |
| Balance sheet | |||||||
| Total assets | - | 817 | 845 | 878 | 1,179 | 1,207 | 1,912 |
| Net worth | - | (35.17) | (5.46) | 39.42 | 364 | 432 | 835 |
| Total debt | - | 376 | 377 | 379 | 359 | 326 | 943 |
| Cash & bank | - | 0.71 | 2.03 | 3.76 | 7.18 | 6.43 | 50.49 |
| Net working capital | - | 232 | 246 | 231 | 432 | 455 | 677 |
| Cash flow | |||||||
| Cash from operations | - | (1.75) | (23.99) | 35.32 | 27.54 | 567 | 79.56 |
| Cash from investing | - | (4.53) | 28.29 | (4.96) | (16.41) | 404 | (196) |
| Cash from financing | - | 4.96 | (6.03) | (33.78) | (10.38) | (1,015) | 72.44 |
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.00 | 15.99 | 20.61 | 21.39 | 25.61 | 36.51 | 24.77 | 29.37 |
| Revenue growth (YoY) | -53.1% | -56.2% | -16.8% | -27.2% | -33.7% | - | - | - |
| Other income | 5.75 | 0.00 | 0.21 | 0.38 | 4.22 | 0.07 | 0.03 | 0.06 |
| EBITDA | (140) | (10.92) | (0.96) | (0.28) | (2.47) | 1.06 | (0.64) | (11.00) |
| EBITDA margin | -1169.0% | -68.3% | -4.7% | -1.3% | -9.6% | +2.9% | -2.6% | -37.5% |
| Depreciation | 11.51 | 4.63 | 4.90 | 5.01 | 5.50 | 6.62 | 4.10 | 4.01 |
| Interest | 0.95 | 1.00 | 1.66 | 0.58 | 1.74 | 0.48 | 0.43 | 0.30 |
| Profit before tax | (147) | (16.55) | (7.31) | (5.49) | (5.49) | (5.97) | (5.14) | (15.25) |
| Tax | 0.14 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 |
| Net profit | (147) | (16.55) | (7.31) | (5.49) | (5.61) | (5.97) | (5.14) | (15.25) |
| EPS (₹) | (17.22) | (1.94) | (0.85) | (0.64) | (0.68) | (0.70) | (0.60) | (1.78) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 55.78 | 104 | 137 | 177 | 218 | 210 | 277 |
| Revenue growth | -46.2% | -24.3% | -22.6% | -19.0% | +4.0% | -24.1% | - |
| EBITDA | (150) | (14.50) | (33.14) | (188) | (9.04) | 27.84 | 32.73 |
| EBITDA margin | -269.1% | -14.0% | -24.2% | -106.3% | -4.1% | +13.3% | +11.8% |
| Profit before tax | (172) | (31.48) | (44.39) | (330) | (64.94) | (23.51) | (20.74) |
| Net profit | (172) | (31.48) | (44.39) | (328) | (67.76) | (23.28) | (12.30) |
| Net profit margin | -307.7% | -30.4% | -32.5% | -185.5% | -31.0% | -11.1% | -4.5% |
| EPS (₹) | (19.98) | (3.80) | (5.35) | (39.56) | (8.17) | (2.81) | (2.31) |
| Balance sheet | |||||||
| Total assets | - | 548 | 593 | 689 | 991 | 1,023 | 993 |
| Net worth | - | 58.49 | 89.41 | 133 | 457 | 524 | 554 |
| Total debt | - | 375 | 375 | 377 | 357 | 323 | 304 |
| Cash & bank | - | 0.29 | 1.14 | 3.35 | 6.78 | 6.02 | 11.09 |
| Net working capital | - | 166 | 197 | 173 | 372 | 395 | 488 |
| Cash flow | |||||||
| Cash from operations | - | 5.73 | (96.52) | 32.87 | 25.31 | 180 | 75.02 |
| Cash from investing | - | (4.06) | 99.83 | (1.60) | (11.34) | (138) | 3.32 |
| Cash from financing | - | (2.53) | (5.51) | (34.70) | (13.21) | (46.40) | (91.42) |
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.55 | 11.63 | 18.66 | 17.94 | 22.58 | 34.23 | 22.16 | 24.64 |
| Revenue growth (YoY) | -66.6% | -66.0% | -15.8% | -27.2% | -38.0% | - | - | - |
| Other income | 0.00 | 0.00 | 0.16 | 0.36 | 4.15 | 0.00 | 0.03 | 0.00 |
| Total expenses | 145 | 22.85 | 19.98 | 18.48 | 25.06 | 34.41 | 22.95 | 35.71 |
| EBITDA | (137) | (11.22) | (1.32) | (0.54) | (2.48) | (0.18) | (0.79) | (11.07) |
| EBITDA margin | -1814.7% | -96.5% | -7.1% | -3.0% | -11.0% | -0.5% | -3.6% | -44.9% |
| Depreciation | 4.31 | 4.40 | 4.68 | 4.80 | 4.61 | 6.37 | 3.86 | 3.79 |
| Interest | 0.79 | 0.94 | 1.60 | 0.52 | 1.48 | 0.43 | 0.37 | 0.25 |
| Profit before tax | (142) | (16.56) | (7.44) | (5.50) | (4.42) | (6.98) | (4.99) | (15.11) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.00 | 15.99 | 20.61 | 21.39 | 25.61 | 36.51 | 24.77 | 29.37 |
| Revenue growth (YoY) | -53.1% | -56.2% | -16.8% | -27.2% | -33.7% | - | - | - |
| Other income | 5.75 | 0.00 | 0.21 | 0.38 | 4.22 | 0.07 | 0.03 | 0.06 |
| EBITDA | (140) | (10.92) | (0.96) | (0.28) | (2.47) | 1.06 | (0.64) | (11.00) |
| EBITDA margin | -1169.0% | -68.3% | -4.7% | -1.3% | -9.6% | +2.9% | -2.6% | -37.5% |
| Depreciation | 11.51 | 4.63 | 4.90 | 5.01 | 5.50 | 6.62 | 4.10 | 4.01 |
| Interest | 0.95 | 1.00 | 1.66 | 0.58 | 1.74 | 0.48 | 0.43 | 0.30 |
| Profit before tax | (147) | (16.55) | (7.31) | (5.49) | (5.49) | (5.97) | (5.14) | (15.25) |
| Tax | 0.14 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 |
| Net profit | (147) | (16.55) | (7.31) | (5.49) | (5.61) | (5.97) | (5.14) | (15.25) |
| EPS (₹) | (17.22) | (1.94) | (0.85) | (0.64) | (0.68) | (0.70) | (0.60) | (1.78) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 69.99 | 116 | 149 | 187 | 237 | 861 | 1,059 |
| Revenue growth | -39.8% | -22.0% | -20.3% | -21.2% | -72.5% | -18.6% | - |
| Other income | 6.32 | 4.37 | 9.98 | 0.97 | 1.27 | 9.82 | 8.26 |
| Total expenses | 222 | 129 | 182 | 374 | 245 | 830 | 1,049 |
| Employee cost | 0.00 | 28.39 | 34.16 | 32.67 | 36.22 | 190 | 233 |
| EBITDA | (152) | (13.01) | (32.88) | (187) | (7.85) | 31.51 | 10.24 |
| EBITDA margin | -217.8% | -11.2% | -22.1% | -99.9% | -3.3% | +3.7% | +1.0% |
| Depreciation | 26.05 | 20.22 | 19.94 | 108 | 18.28 | 55.50 | 66.95 |
| Interest | 4.17 | 2.98 | 2.98 | 36.23 | 39.99 | 55.70 | 61.03 |
| Profit before tax | (176) | (31.84) | (45.82) | (331) | (64.85) | (69.87) | (109) |
| Tax | 0.14 | 0.12 | (0.38) | (2.12) | 2.82 | 2.03 | (0.36) |
| Net profit | (176) | (31.96) | (45.44) | (329) | (67.67) | (71.90) | (109) |
| Net profit margin | -252.1% | -27.5% | -30.5% | -175.6% | -28.5% | -8.4% | -10.3% |
| EPS (₹) | (20.53) | (3.85) | (5.48) | (39.62) | (8.16) | (8.67) | (13.16) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 16.58 | 16.58 | 16.58 | 16.58 | 16.58 | 342 |
| Reserves & surplus | - | (51.75) | (22.04) | 22.84 | 348 | 415 | 493 |
| Shareholders' funds (net worth) | - | (35.17) | (5.46) | 39.42 | 364 | 432 | 835 |
| Minority interest | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | - | 313 | 314 | 317 | 298 | 269 | 833 |
| Unsecured loans | - | 63.32 | 63.32 | 61.98 | 60.61 | 56.27 | 110 |
| Total debt | - | 376 | 377 | 379 | 359 | 326 | 943 |
| Total liabilities | - | 817 | 845 | 878 | 1,179 | 1,207 | 1,912 |
| Assets | |||||||
| Gross block | - | 752 | 742 | 740 | 802 | 766 | 1,274 |
| Net block | - | 408 | 418 | 436 | 520 | 502 | 1,045 |
| Capital work in progress | - | 17.11 | 20.65 | 20.67 | 40.03 | 60.12 | 89.28 |
| Investments | - | 168 | 168 | 199 | 199 | 199 | 85.71 |
| Inventories | - | 58.76 | 64.06 | 161 | 241 | 256 | 502 |
| Sundry debtors | - | 74.11 | 82.82 | 74.16 | 87.36 | 108 | 249 |
| Cash & bank balances | - | 0.71 | 2.03 | 3.76 | 7.18 | 6.43 | 50.49 |
| Loans & advances | - | 194 | 194 | 181 | 172 | 159 | 174 |
| Total current assets | - | 328 | 343 | 420 | 507 | 529 | 975 |
| Total current liabilities | - | 95.48 | 96.97 | 189 | 75.50 | 73.25 | 298 |
| Net working capital | - | 232 | 246 | 231 | 432 | 455 | 677 |
| Total assets | - | 817 | 845 | 878 | 1,179 | 1,207 | 1,912 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 2.03 | 3.76 | 7.18 | 6.43 | 50.49 | 94.50 |
| Net cash from operating activities | - | (1.75) | (23.99) | 35.32 | 27.54 | 567 | 79.56 |
| Net cash from investing activities | - | (4.53) | 28.29 | (4.96) | (16.41) | 404 | (196) |
| Net cash from financing activities | - | 4.96 | (6.03) | (33.78) | (10.38) | (1,015) | 72.44 |
| Net change in cash | - | (1.32) | (1.74) | (3.42) | 0.75 | (44.06) | (44.02) |
| Closing cash | - | 0.71 | 2.03 | 3.76 | 7.18 | 6.43 | 50.49 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -39.8% | -22.0% | -20.3% | -21.2% | -72.5% | -18.6% | - |
| EBITDA growth | -1071.6% | +60.4% | +82.4% | -2282.0% | -124.9% | +207.7% | - |
| PBT growth | -453.8% | +30.5% | +86.1% | -409.9% | +7.2% | +36.2% | - |
| Net income growth | -452.2% | +29.7% | +86.2% | -385.5% | +5.9% | +34.1% | - |
| Revenue CAGR (3Y) | -28.0% | -21.2% | -44.3% | -43.9% | -43.5% | -10.1% | -10.2% |
| EBITDA CAGR (3Y) | -6.6% | +18.3% | - | - | - | -47.3% | -70.6% |
| Profitability & leverage | |||||||
| Net income margin | -252.1% | -27.5% | -30.5% | -175.6% | -28.5% | -8.4% | -10.3% |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | -2.2% | -0.9% | -2.6% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | -18.8% | -16.6% | -20.8% |
| Debt / equity | - | 0.00 | 0.00 | 2.25 | 0.95 | 1.07 | 1.11 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.38 | 0.17 | 0.44 | 0.53 |
| Interest cover | -2.34 | -8.97 | -5.64 | -12.26 | -153.04 | -232.18 | -107.62 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.16 | 0.21 | 0.26 | 0.32 | 0.88 | 0.90 |
| Inventory turnover | - | 1.89 | 1.33 | 0.93 | 0.96 | 2.27 | 1.99 |
| Debtors turnover | - | 1.48 | 1.90 | 2.32 | 2.44 | 4.83 | 3.50 |
| EPS (₹) | (20.53) | (3.85) | (5.48) | (39.62) | (8.16) | (8.67) | (13.16) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | (8.82) | (5.24) | 0.17 | 39.35 | 47.47 | 56.85 |
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.55 | 11.63 | 18.66 | 17.94 | 22.58 | 34.23 | 22.16 | 24.64 |
| Revenue growth (YoY) | -66.6% | -66.0% | -15.8% | -27.2% | -38.0% | - | - | - |
| Other income | 0.00 | 0.00 | 0.16 | 0.36 | 4.15 | 0.00 | 0.03 | 0.00 |
| Total expenses | 145 | 22.85 | 19.98 | 18.48 | 25.06 | 34.41 | 22.95 | 35.71 |
| EBITDA | (137) | (11.22) | (1.32) | (0.54) | (2.48) | (0.18) | (0.79) | (11.07) |
| EBITDA margin | -1814.7% | -96.5% | -7.1% | -3.0% | -11.0% | -0.5% | -3.6% | -44.9% |
| Depreciation | 4.31 | 4.40 | 4.68 | 4.80 | 4.61 | 6.37 | 3.86 | 3.79 |
| Interest | 0.79 | 0.94 | 1.60 | 0.52 | 1.48 | 0.43 | 0.37 | 0.25 |
| Profit before tax | (142) | (16.56) | (7.44) | (5.50) | (4.42) | (6.98) | (4.99) | (15.11) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 55.78 | 104 | 137 | 177 | 218 | 210 | 277 |
| Revenue growth | -46.2% | -24.3% | -22.6% | -19.0% | +4.0% | -24.1% | - |
| Other income | 0.51 | 4.19 | 9.57 | 0.24 | 1.26 | 6.08 | 6.54 |
| Total expenses | 206 | 118 | 170 | 365 | 227 | 182 | 244 |
| Employee cost | 0.00 | 23.04 | 29.45 | 29.67 | 31.68 | 26.45 | 31.87 |
| EBITDA | (150) | (14.50) | (33.14) | (188) | (9.04) | 27.84 | 32.73 |
| EBITDA margin | -269.1% | -14.0% | -24.2% | -106.3% | -4.1% | +13.3% | +11.8% |
| Depreciation | 18.19 | 18.63 | 18.41 | 107 | 17.45 | 15.80 | 16.57 |
| Interest | 3.86 | 2.54 | 2.41 | 35.55 | 39.71 | 41.63 | 43.44 |
| Profit before tax | (172) | (31.48) | (44.39) | (330) | (64.94) | (23.51) | (20.74) |
| Tax | 0.00 | 0.00 | 0.00 | (2.12) | 2.82 | (0.23) | (1.57) |
| Net profit | (172) | (31.48) | (44.39) | (328) | (67.76) | (23.28) | (12.30) |
| Net profit margin | -307.7% | -30.4% | -32.5% | -185.5% | -31.0% | -11.1% | -4.5% |
| EPS (₹) | (19.98) | (3.80) | (5.35) | (39.56) | (8.17) | (2.81) | (2.31) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 16.58 | 16.58 | 16.58 | 16.58 | 16.58 | 16.58 |
| Reserves & surplus | - | 41.91 | 72.83 | 117 | 441 | 508 | 537 |
| Shareholders' funds (net worth) | - | 58.49 | 89.41 | 133 | 457 | 524 | 554 |
| Secured loans | - | 312 | 312 | 315 | 296 | 267 | 200 |
| Unsecured loans | - | 63.32 | 63.32 | 61.98 | 60.61 | 56.27 | 104 |
| Total debt | - | 375 | 375 | 377 | 357 | 323 | 304 |
| Total liabilities | - | 548 | 593 | 689 | 991 | 1,023 | 993 |
| Assets | |||||||
| Gross block | - | 514 | 507 | 505 | 566 | 536 | 463 |
| Net block | - | 315 | 326 | 343 | 429 | 416 | 356 |
| Capital work in progress | - | 17.11 | 20.65 | 20.67 | 40.03 | 58.45 | 69.77 |
| Investments | - | 58.78 | 58.78 | 161 | 161 | 161 | 87.50 |
| Inventories | - | 56.50 | 62.77 | 78.31 | 239 | 254 | 263 |
| Sundry debtors | - | 45.80 | 59.54 | 50.30 | 63.39 | 76.70 | 89.67 |
| Cash & bank balances | - | 0.29 | 1.14 | 3.35 | 6.78 | 6.02 | 11.09 |
| Loans & advances | - | 145 | 152 | 139 | 133 | 122 | 190 |
| Total current assets | - | 248 | 276 | 271 | 442 | 459 | 554 |
| Total current liabilities | - | 81.70 | 79.02 | 97.83 | 69.49 | 63.73 | 65.29 |
| Net working capital | - | 166 | 197 | 173 | 372 | 395 | 488 |
| Total assets | - | 548 | 593 | 689 | 991 | 1,023 | 993 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 1.14 | 3.35 | 6.78 | 6.02 | 11.09 | 24.16 |
| Net cash from operating activities | - | 5.73 | (96.52) | 32.87 | 25.31 | 180 | 75.02 |
| Net cash from investing activities | - | (4.06) | 99.83 | (1.60) | (11.34) | (138) | 3.32 |
| Net cash from financing activities | - | (2.53) | (5.51) | (34.70) | (13.21) | (46.40) | (91.42) |
| Net change in cash | - | (0.86) | (2.20) | (3.43) | 0.76 | (5.07) | (13.07) |
| Closing cash | - | 0.29 | 1.14 | 3.35 | 6.78 | 6.02 | 11.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -46.2% | -24.3% | -22.6% | -19.0% | +4.0% | -24.1% | - |
| EBITDA growth | -935.0% | +56.3% | +82.4% | -1978.5% | -132.5% | -14.9% | - |
| PBT growth | -445.2% | +29.1% | +86.6% | -408.4% | -176.2% | -13.4% | - |
| Net income growth | -445.2% | +29.1% | +86.5% | -384.1% | -191.1% | -89.3% | - |
| Revenue CAGR (3Y) | -31.9% | -22.0% | -13.3% | -13.9% | -4.6% | -7.0% | -21.4% |
| EBITDA CAGR (3Y) | -7.2% | +17.1% | - | - | - | -29.2% | -49.3% |
| Profitability & leverage | |||||||
| Net income margin | -307.7% | -30.4% | -32.5% | -185.5% | -31.0% | -11.1% | -6.9% |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | -2.6% | +1.9% | +3.0% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | -15.0% | -4.7% | -2.3% |
| Debt / equity | - | 10.44 | 5.13 | 1.43 | 0.75 | 0.63 | 0.62 |
| Long-term debt / equity | - | 1.76 | 0.85 | 0.24 | 0.13 | 0.12 | 0.15 |
| Interest cover | -2.29 | -7.67 | -4.68 | -12.06 | -149.91 | 345.76 | 268.81 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.22 | 0.29 | 0.36 | 0.43 | 0.46 | 0.64 |
| Inventory turnover | - | 1.74 | 1.94 | 1.11 | 0.89 | 0.81 | 1.01 |
| Debtors turnover | - | 1.97 | 2.49 | 3.11 | 3.12 | 2.53 | 2.89 |
| EPS (₹) | (19.98) | (3.80) | (5.35) | (39.56) | (8.17) | (2.81) | (2.31) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 2.47 | 6.20 | 11.50 | 50.57 | 58.67 | 62.22 |
To see the full year-wise statements and ratios of Vivimed Labs Limited, buy the company report.
Board of directors of Vivimed Labs Limited
Vivimed Labs has 6 current directors and 25 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manohar Rao Varalwar | Whole-Time Director | 14 Aug 2015 | 11 Years 2 Months | As last reported |
| Sandeep Varalwar Also directs: B B R Projects Private Limited | Whole-Time Director | 27 Sep 2008 | 18 Years 0 Months | As last reported |
| Santosh Varalwar Also directs: B B R Projects Private Limited, Uquifa India Private Limited, Kreative Hosts Atria Private Limited and 2 more | Managing Director | 09 Nov 1989 | 36 Years 11 Months | As last reported |
| Aparna Bidarkar Also directs: Finoso Pharma Private Limited, Lattice Projex Private Limited | Director | 14 Feb 2022 | 4 Years 8 Months | As last reported |
| Siva Prasad Jarugula | Director | 11 Dec 2024 | 1 Years 10 Months | As last reported |
| Subbarathnamma Palepu Also directs: Ahlada Engineers Limited, GSS Infotech Limited, More Agrisupplies & Services Private Limited and 3 more | Director | 11 Dec 2024 | 1 Years 10 Months | As last reported |
Peer comparison
Vivimed Labs Limited is compared with the 8 companies closest to it by revenue in the FMCG industry (API Manufacturers, Personal Care and Skin Care), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Richter Themis Medicare (India) Private Limited | ₹122.69 Cr (FY 2025) | -13.0% | Valsad, Gujarat, India | |||
| Nuray Chemicals Private Limited | ₹122.27 Cr (FY 2025) | 16.0% | Thiruvallur, Tamil Nadu, India | |||
| Glenfin Chemicals Private Limited | ₹121.15 Cr (FY 2023) | 21.0% | Thane, Maharashtra, India | |||
| Anlon Healthcare Limited | ₹120.46 Cr (FY 2025) | 81.0% | Rajkot, Gujarat, India | |||
| Kimia Biosciences Limited | ₹120.24 Cr (FY 2025) | 13.0% | Gurgaon, Haryana, India | |||
| Galaxy Laboratories Private Limited | ₹120.18 Cr (FY 2025) | 17.0% | Aurangabad, Maharashtra, India | |||
| Vartika Chemicals & Pharmaceuticals Private Limited | ₹120.07 Cr (FY 2025) | -17.0% | New Delhi, Delhi, India | |||
| Accra Pac (India) Private Limited | ₹120.05 Cr (FY 2025) | -10.0% | Vapi, Gujarat, India | |||
| Vivimed Labs Limitedthis company | ₹69.99 Cr (FY 2026) | -₹176.47 Cr | -252.1% | -39.8% | 59 | Bidar, Karnataka, India |
To see the full peer comparison of Vivimed Labs Limited, buy the company report.
Auditor
Vivimed Labs Limited is audited by SVRL & Co Chartered Accountants for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SVRL & Co Chartered Accountants | FY 2024 | 016182S |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 7.60%, foreign institutional investors hold 1.60%, domestic institutional investors hold 0.20% and retail and other public shareholders hold 90.70%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 7.60% | 7.80% | 7.80% | 7.80% |
| Public | 92.40% | 92.20% | 92.20% | 92.20% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 17 Dec 2020 | 100409055 | Others | ₹232 Cr | Open | |
| 29 Jul 2020 | 100354963 | Others | ₹15 Cr | Open | |
| 08 Nov 2017 | 100135885 | State Bank of India | ₹4.5 Cr | Open | |
| 02 Apr 2015 | 10567195 | Corporation Bank | ₹16 Lakh | Open | |
| 25 Sep 2014 | 10525983 | State Bank of Hyderabad | ₹5.75 Cr | Open |
To see the full charge records of Vivimed Labs Limited, buy the company report.
Total charge records: 46 View all charges
Deals & funding
Vivimed Labs Limited has 159 deals on record (151 market trades, 7 funding rounds, 1 secondary share transfer), with disclosed funding of ₹181.1 Cr; the latest was in February 2026.
Deals on record (5 of 159)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2026 | Market trade | ₹43.1 Lakh | Buyer: Krone Finstock Private Limited Seller: Krone Finstock Private Limited |
| Jan 2026 | Market trade | ₹1.84 Cr | Buyer: Neo Apex Venture LLP , Meru Investments Seller: Neo Apex Venture LLP |
| Jun 2022 | Market trade | ₹42.3 Lakh | Seller: Dhansafal Finserve Limited |
| Mar 2022 | Market trade | ₹65.3 Lakh | Seller: Krone Finstock Private Limited |
| Jan 2022 | Market trade | ₹86.4 Lakh | Seller: Sbicap Trustee Company Limited |
To see the full deal history of Vivimed Labs Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Vivimed Labs Limited has 131 court cases on record: 20 filed by Vivimed Labs, 111 filed against it. 35 cases are pending and 96 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 85 | 83 | 27 |
| High courts | 43 | 25 | 8 |
| Supreme Court | 2 | 2 | 0 |
| NCLT | 1 | 1 | 0 |
Cases on record (5 of 131)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Medchal Malkajgiri, Telangana | Civil suit | Filed against the company by Mr Laboratories Pvt Ltd | Pending |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by M/S Biocon Limited | Pending |
| District court, North West, Delhi | Court case (CS (COMM.)) | Filed against the company by M/S A/C/ Surgipharma Pvt Ltd | Pending |
| District court, Calcutta, West Bengal | Civil suit | Filed against the company by Ms H L Sett and Sons Pvt Ltd | Pending |
| District court, Medchal Malkajgiri, Telangana | Civil suit | Filed against the company by Spansules Pharmatech Pvt Ltd. | Disposed |
To see the full case history of Vivimed Labs Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Vivimed Labs Limited was last rated by Care on 24 May 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 24 May 2022 |
To see the full credit ratings and regulatory alerts of Vivimed Labs Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Vivimed Labs Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Vivimed Labs has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Finoso Pharma Private Limited | U24231TG2009PTC064774 |
To see the full group structure of Vivimed Labs Limited, buy the company report.
Employees & EPFO
Vivimed Labs Limited has a workforce of 59 employees on its EPFO records as of Apr 05, 2025, across 9 active EPFO establishments.
GST
Vivimed Labs has 10 GST registrations: 7 active and 3 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAACV6060A1ZL | Karnataka | Active | 01 Jul 2017 |
| 05AAACV6060A1ZV | Uttarakhand | Active | 01 Jul 2017 |
| 09AAACV6060A1ZN | Uttar Pradesh | Active | 01 Jul 2017 |
| 19AAACV6060A1ZM | West Bengal | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Vivimed Labs Limited, buy the company report.
Recent activity
Vivimed Labs Limited has 53 board changes on record since 1989: 30 appointments and 23 cessations. The latest: Phaninder Nath Peta Sonti was appointed as CFO on 23 Jan 2025.
145 earlier events are in the company report.
News
Frequently asked questions
Vivimed Labs is undergoing "Corporate Insolvency Resolution Process" (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency resolution professional. The company may not be able to independently enter into new commitments during this period. This is a high-risk status - verify the resolution status before any engagement.
Vivimed Labs is a company under insolvency, formerly operating as a public limited company based in Bidar, Karnataka, India. The company works in personal care and skincare products, within the FMCG industry. It was incorporated on 22 September 1988 and is registered under CIN L02411KA1988PLC009465. Listed on BSE: 532660 and NSE: VIVIMEDLAB. Caution is advised - the company may not have the legal capacity to fulfil new agreements.
Vivimed Labs reported revenue of ₹69.99 Cr for FY 2025-26 (down 39.8% YoY) based on consolidated financials.
Vivimed Labs has 6 current directors:
- Santosh Varalwar - Managing Director
- Manohar Rao Varalwar - Whole-Time Director
- Sandeep Varalwar - Whole-Time Director
- Aparna Bidarkar - Director
- Siva Prasad Jarugula - Director
- Subbarathnamma Palepu - Director
The latest financial statements of Vivimed Labs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Vivimed Labs is L02411KA1988PLC009465. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Vivimed Labs is a listed company as per MCA records. Its shares are listed on both BSE (code: 532660) and NSE (symbol: VIVIMEDLAB).
Vivimed Labs has open charges of ₹932.51 Cr and satisfied charges of ₹791.99 Cr as per latest MCA filings.
Vivimed Labs has 131 court cases on record: 20 filed by the company and 111 filed against it. 35 are pending. Most are in the district courts.
Vivimed Labs was incorporated on 22 September 1988. It is registered with the Registrar of Companies, Bangalore.
Vivimed Labs has 159 deals on record (151 market trades, 7 funding rounds, 1 secondary share transfer), with disclosed funding of ₹181.1 Cr; the latest was in February 2026.